Children's Hospital Colorado
Alisa Lee-Sherick, MD
Cancer and Blood Disorders

Alisa Lee-Sherick, MD

Assistant Professor

Specialties:
Hematology/Oncology - Pediatric , Pediatrics
Conditions:
Aplastic Anemia, Pediatric Cancer, Lymphoma, Leukemia (Childhood), Blood and Marrow Transplant
specialties:

Hematology/Oncology - Pediatric , Pediatrics

conditions:

Aplastic Anemia, Pediatric Cancer, Lymphoma, Leukemia (Childhood), Blood and Marrow Transplant

Meet Alisa Lee-Sherick, MD

It is amazing to look back 30-40 years and see how much progress we have made in the clinical care of pediatric patients with cancer. My goal, both clinically and through my research, is to continue to improve survival rates and figure out how to minimize toxicities of our cancer fighting therapies. I believe that this progress includes both the use of new/novel treatment options, as well as collaborating with families to determine the best care plan for their children.

Get to know her background

My clinical interest is in stem cell transplantation & cellular therapy for relapsed or refractory pediatric cancers.

Undergraduate 1999

University of Minnesota–Twin Cities (MN)

Medical School 2006

University of Minnesota Medical School

Internship 2007

Children's Hospital of Orange County Program

Residency 2009

Oregon Health & Science University, Pediatrics

Fellowship 2012

University of Colorado (Children's Hospital Colorado) Program, Pediatric Hematology / Oncology

Pediatric Scientist Development Program Fellow 2013

The Association of Medical School Pediatric Department Chairs Inc. (AMSPDC)

Scholar 2015

University of Colorado Department of Pediatrics K12

Junior Faculty Scholar 2018

American Society of Hematology

For Patients:
Dr. Lee-Sherick is a Pediatric Bone Marrow Transplant specialist at Children's Hospital Colorado. Dr. Lee Sherick's primary research focus is to harness the immune system to more effectively cure acute leukemia. The Lee Sherick lab explores the role that tolerogenic macrophages and dendritic cells play in immune evasion of leukemia and how this can be reversed. One such approach is by inhibiting efferocytosis by blocking phosphatidyl serine receptors (such as MerTK) on macrophages and dendritic cells, which results in an anti-tumor microenvironment and decreases immune evasion. The hope is that the knowledge gained from this research can be used to develop novel immunotherapeutic approaches to treat acute leukemias.
For Referring Providers:
My research interest focuses on pediatric acute leukemias.

Assistant Professor


PRODWEBSERVER1